{"classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"71"}],"units":"Participants"}],"description":"Incidence of Grade 3 or higher infusion-related reactions for patients receiving 60-minute or 30-minute infusions of margetuximab in Cycle 2 of treatment","groups":[{"description":"Margetuximab 15 mg/kg administered every 21 days with physician's choice of 1 of 4 backbone chemotherapy regimens.","id":"OG000","title":"Margetuximab Plus Chemotherapy"},{"description":"Trastuzumab administered every 21 days with physician's choice of 1 of 4 backbone chemotherapy regimens.","id":"OG001","title":"Trastuzumab Plus Chemotherapy"},{"description":"Margetuximab administered as a 120 minute first infusion in Cycle 1 followed by 60 minute infusion in Cycle 2.","id":"OG002","title":"Margetuximab Stage A1"},{"description":"Margetuximab administered as a 120 minute first infusion in Cycle 1 followed by 30 minute infusion in Cycle 2.","id":"OG003","title":"Margetuximab Stage A2"},{"description":"Margetuximab administered as a 120 minute first infusion in Cycle 1 followed by 30 minute infusion in Cycle 2.","id":"OG004","title":"Margetuximab Stage B"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only patients in the infusion substudy are included in this outcome measure.","reportingStatus":"POSTED","timeFrame":"22 days","title":"Number of Patients With Grade 3 or Higher Infusion Related Reactions","type":"PRIMARY","unitOfMeasure":"Participants"}